Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: Definitions and epidemiology

American Journal of Medicine

Volumn 105, Issue 5 A, 1998, Pages 3S-9S

  McCarthy, Denis ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; DYSPEPSIA; EPIDEMIOLOGY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GASTROSCOPY; HEARTBURN; HUMAN; PAIN; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

EID: 0032476644     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(98)00274-5     Document Type: Conference Paper

References (65)

1. Gabriel S.E., Fehring R.A. Trends in the utilization of non-steroidal anti-inflammatory drugs in the United States, 1986-1990. J Clin Epidemiol. 45:1992;1041-1044.
2. Fries J.F. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol. 18:(suppl 28):1991;6-10.
3. Lanas A.I., Arroyo M.T., Esteva F., et al. Aspirin related gastrointestinal bleeders have an exaggerated bleeding time response due to aspirin use. Gut. 39:1996;654-660.
4. Levy M., Miller D.R., Kaufman D.W., et al. Major upper gastrointestinal tract bleeding relation to the use of aspirin and other nonnarcotic analgesics . Arch Intern Med. 148:1988;281-285.
5. Graham D.Y., Smith J.L. Aspirin and the stomach. Ann Intern Med. 104:1986;390-398.
6. Schafer A.I. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 35:1995;209-219.
7. García Rodríguez L.A., Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet. 343:1994;769-772.
8. Henry D., Dobson A., Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology. 105:1993;1078-1088.
9. Henry D., Page J., Whyte I., et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects results of a case-control study . Br J Clin Pharmacol. 44:1997;85-90.
10. Lanas A., Serrano P., Bajador E., et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology. 112:1997;683-689.
11. Gabriel S.E., Jaakkimainen L., Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs a meta-analysis . Ann Intern Med. 115:1991;787-796.
12. Armstrong C.P., Blower A.L. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut. 28:1987;527-532.
13. Larkai E.N., Smith J.L., Lidsky M.D., Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 82:1987;1153-1158.
14. Graham D.Y., Smith J.L. Gastroduodenal complications of chronic NSAID therapy. Am J Gastroenterol. 83:1988;1081-1084.
15. McCarthy D.M. Nonsteroidal antiinflammatory drug-induced ulcers management by traditional therapies . Gastroenterology. 96:(suppl):1989;662-674.
16. Griffin M.R., Piper J.M., Daugherty J.R., et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med. 114:1991;257-263.
17. Soll A.H., Weinstein W.M., Kurata J., McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med. 114:1991;307-319.
18. Paulus H.E. FDA Arthritis Committee Meeting serious gastrointestinal toxicity of nonsteroidal/anti-inflammatory drugs; drug-containing renal and biliary stones; diclofenac and carprofen approved . Arthritis Rheum. 31:1988;1450-1451.
19. Temple R. Quoted in: FDA's NSAID G-I warning. Scrip. December 15, 1986; No. 1163:11.
20. Labeling revisions for NSAIDs. FDA Drug Bulletin. February, 1989;19:3-4.
21. MacDonald T.M., Morant S.V., Robinson G.C., et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure cohort study . BMJ. 315:1997;1333-1337.
22. Tympner F. Gastroscopic findings after therapy with non-steroid antirheumatic drugs. Z Rheumatol. 40:1981;179-181.
23. Kikendall J.W., Friedman A.C., Oyewole M.A., et al. Pill-induced esophageal injury case reports and review of the medical literature . Dig Dis Sci. 28:1983;174-182.
24. Heller S.R., Fellows I.W., Ogilvie A.L., Atkinson M. Non-steroidal anti-inflammatory drugs and benign oesophageal stricture. BMJ. 285:1982;167-168.
25. Banerjee A.K. Enteropathy induced by non-steroidal anti-inflammatory drugs. BMJ. 298:1989;1539-1540.
26. Lanas A., Sekar M.C., Hirschowitz B.I. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology. 103:1992;862-869.
27. Langman M.J.S., Morgan L., Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed). 290:1985;347-349.
28. Bijlsma J. Treatment of endoscopy-negative NSAID-induced upper gastrointestinal symptoms with cimetidine. Aliment Pharmacol Ther. 2:(suppl 1):1988;75-83.
29. Taha A.S., Dahill S., Sturrock R.D., et al. Predicting NSAID related ulcers assessment of clinical and pathological risk factors and importance of differences in NSAID . Gut. 35:1994;891-895.
30. Simon L.S., Hatoum H.T., Bittman R.M., et al. Risk factors for serious nonsteroidal-induced gastrointestinal complications regression analysis of the MUCOSA trial . Fam Med. 28:1996;204-210.
31. Bijlsma J.W. Treatment of NSAID-induced gastrointestinal lesions with cimetidine an international multicentre collaborative study . Aliment Pharmacol Ther. 2S:1988;85-95.
32. Olivero J.J., Graham D.Y. Gastric adaptation to nonsteroidal anti-inflammatory drugs in man. Scand J Gastroenterol. 27:(suppl 193):1992;53-58.
33. Wallin B.A., Grier C.E., Fox M.J., et al. Prevention of NSAID-induced ulcers with cimetidine results of a double-blind, placebo controlled trial . (Abstr.) Gastroenterology. 98:(suppl):1990;A146.
34. Hawkey C.J. Non-steroidal anti-inflammatory drugs and peptic ulcers facts and figures multiply, but do they add up? BMJ. 300:1990;278-284.
35. Griffin M.R., Ray W.A., Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 109:1988;359-363.
36. Carson J.L., Strom B.L., Soper K.A., et al. The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med. 147:1987;85-88.
37. Fries J.F., Williams C.A., Bloch D.A., Michel B.A. Nonsteroidal anti-inflammatory drug-associated gastropathy incidence and risk factor models . Am J Med. 91:1991;213-222.
38. Piper J.M., Ray W.A., Daugherty J.R., Griffin M.R. Corticosteroid use and peptic ulcer disease role of nonsteroidal anti-inflammatory drugs . Ann Intern Med. 114:1991;735-740.
39. Shorr R.I., Ray W.A., Daugherty J.R., Griffin M.R. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med. 153:1993;1665-1670.
40. Davies N.M., Wallace J.L. Selective inhibitors of cyclooxygenase-2. Potential in elderly patients. Drugs Aging. 9:1996;406-417.
41. Hochain P., Berkelmans I., Czernichow P., et al. Which patients taking non-aspirin non-steroidal anti-inflammatory drugs bleed? A case-control study. Eur J Gastroenterol Hepatol. 7:1995;419-426.
42. Orlando R.C. Peptic ulcer factors influencing recurrence . J Clin Gastroenterol. 9:(suppl 1):1987;2-7.
43. Lindell G., Farnebo L.O., Chen D., et al. Acute effects of smoking during modified sham feeding in duodenal ulcer patients an analysis of nicotine, acid secretion, gastrin, catecholamines, epidermal growth factor, prostaglandin E2, and bile acids . Scand J Gastroenterol. 28:1993;487-494.
44. Baumeister B., Schmidt C., Schiermeyer-Dunkhase B., et al. Decreased gastric prostaglandin E2 synthesis in patients with gastric ulcers and in smokers. Hepatogastroenterology. 42:1995;851-855.
45. Willoughby J.M., Essigman W.K., Weber J.C., Pineura R.F. Smoking and peptic ulcer in rheumatoid arthritis. Clin Exp Rheumatol. 4:1986;31-35.
46. Yeomans N.D., Elliott S.L., Edwards J., et al. Gastroduodenal damage during therapy with nonsteroidal antiinflammatory drugs prevalence in arthritis clinic patients and effect of smoking . (Abstr.) Gastroenterology. 94:1988;A510.
47. Farah D., Sturrock R.D., Russell R.I. Peptic ulcer in rheumatoid arthritis. Ann Rheum Dis. 47:1988;478-480.
48. Ekstrom P., Carling L., Wetterhus S., et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy a Nordic multicentre study . Scand J Gastroenterol. 31:1996;753-758.
49. Chan F.K., Sung J.J., Chung S.C., et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 350:1997;975-979.
50. Wagstaff A.J., Benfield P., Monk J.P. Colloidal bismuth subcitrate a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease . Drugs. 36:1988;132-157.
51. Fries J.F., Williams C.A., Bloch D.A. The relative toxicity of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 34:1991;1353-1360.
52. Henry D., Lim L.L.-Y., García Rodríguez L.A., et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs results of a collaborative meta-analysis . BMJ. 312:1996;1563-1566.
53. Singh G., Terry R., Ramey D.R., et al. Comparative GI toxicity of NSAIDs. (Abstr.) Arthritis Rheum. 40:(suppl):1997;S115.
54. Distel M., Mueller C., Bluhmki E., Fries J. Safety of meloxicam a global analysis of clinical trials . Br J Rheumatol. 35:(suppl 1):1996;68-77.
55. Lanza F.L., Rack M.F., Callison D.A., et al. A pilot endoscopic study of the gastroduodenal effects of SC-58635, a novel COX-2-selective inhibitor. (Abstr.) Gastroenterology. 112:(suppl):1997;A194.
56. Blower P.R. Non-steroidal anti-inflammatory drugs. Br J Rheumatol. 32:(suppl 4):1993;35-38.
57. 3-adrenoceptor agonist CL316243 prevents indomethacin-induced jejunal ulceration in the rat by reversing early villous shortening. J Pathol. 179:1996;340-346.
58. 3 adrenergic agonists prevents indomethacin-induced antral ulcer in the rat. J Pharmacol Exp Ther. 270:1994;559-565.
59. Reuter B.K., Davies N.M., Wallace J.L. Nonsteroidal anti-inflammatory drug enteropathy in rats role of permeability, bacteria, and enterohepatic circulation . Gastroenterology. 112:1997;109-117.
60. Brune K., Nürnberg B., Szelenyi I., Vergin H. The enterohepatic circulation of some anti-inflammatory drugs may cause intestinal ulcerations. Rainsford K.D., Velo G.P. Side-Effects of Anti-inflammatory Drugs. Part II Studies in Major Organ Systems . 1987;29-39 MTP Press, Lancaster.
61. Pérez Gutthann S., García Rodríguez L.A., Raiford D.S., et al. Non-steroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med. 156:1996;2433-2439.
62. Leufkens H.G., Ameling C.B., Hekster Y.A., Bakker A. Utilization patterns of non-steroidal anti-inflammatory drugs in an open Dutch population. Pharm Weekbl Sci. 12:1990;97-103.
63. Peura D.A., Lanza F.L., Gostout C.J., Foutch P.G. The American College of Gastroenterology Bleeding Registry preliminary findings . Am J Gastroenterol. 92:1997;924-928.
64. Wilcox C.M., Shalek K.A., Cotsonis G. Striking prevalence of over-the-counter nonsteroidal anti-inflammatory drug use in patients with upper gastrointestinal hemorrhage. Arch Intern Med. 154:1994;42-46.
65. Saleeby G., Holt L., Holt S. Pattern and prevalence of non-steroidal anti-inflammatory drug (NSAID) use in complicated peptic ulcer disease (CPUD). (Abstr.) Gastroenterology. 100:(suppl):1991;A17.